Newsroom
Sorted by: Latest
-
CRH plc UK Regulatory Announcement: Transaction in Own Shares
NEW YORK--(BUSINESS WIRE)-- 5th January, 2026 CRH plc Transaction in Own Shares CRH plc (“CRH”) announces that on 2nd January 2026 it acquired the following number of its ordinary shares (the “ordinary shares”) in the United States through CRH’s broker Santander US Capital Markets LLC. The ordinary shares acquired (by way of redemption) will be cancelled. Aggregate number of ordinary shares acquired Daily volume weighted average price paid Daily highest price paid per share Daily lowest price...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Rising Dividend Achievers UCITS ETF 02.01.2026 RDVY LN IE000K5F6EL4 525,002.00 USD 11,672,606.26 22.234 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - June 02.01.2026 QJUN.LN IE000HFBJ0U0 3,400,002.00 USD 73,310,857.79 21.562 ...
-
Le Groupe Acrelec annonce un changement dans son équipe de direction
CHICAGO--(BUSINESS WIRE)--Groupe Acrelec, leader mondial des bornes de commande et des solutions digitales pour les enseignes de restauration rapide (QSR) et de retail, annonce aujourd’hui une transition majeure au sein de son équipe dirigeante, alors que l’entreprise ambitionne d’accélérer sa croissance mondiale. Après avoir guidé Acrelec depuis ses débuts en tant que start-up jusqu’à sa position actuelle de leader mondial dans les technologies, Jacques Mangeot, cofondateur, président et PDG,...
-
River Global Investors LLP UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: River Global Investors LLP 213800HIGHFCAY9K8Z97 (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and bene...
-
Glory Global Solutions Announces Executive Leadership Changes in Subsidiary Acrelec Group
BASINGSTOKE, England--(BUSINESS WIRE)--Glory Global Solutions has today announced a major change in executive leadership at its subsidiary, Acrelec, as the company prepares to drive accelerated growth on a global scale. After guiding Acrelec from its origins as a start-up to its present position as a global technology leader, co-founder, President and CEO Jacques Mangeot has stepped down from his roles and left the business. The company expresses its deep appreciation for Jacques’ vision, leade...
-
Samsung Bioepis beginnt mit der Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis (Ranibizumab), in Europa
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen mit der direkten Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis1 (Ranibizumab), in Europa begonnen hat. Samsung Bioepis hat daran gearbeitet, eine nahtlose Übertragung der Vermarktungsrechte von Biogen zurück an Samsung Bioepis sicherzustellen, und BYOOVIZ wird nun in mehreren europäischen Ländern als Marke von Samsung Bioepis erhältlich sein. „Dies ist ein wichtiger Meilenstein für Samsun...
-
Resumen: Samsung Bioepis inicia la comercialización de BYOOVIZ®, biosimilar de Lucentis (ranibizumab) en Europa
INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. acaba de anunciar que la empresa ha iniciado la comercialización directa de BYOOVIZ®, un biosimilar de Lucentis1 (ranibizumab) en Europa. Samsung Bioepis ha venido trabajando para garantizar una fluida transferencia de los derechos comerciales de Biogen de vuelta a Samsung Bioepis, y BYOOVIZ estará ahora disponible como marca de Samsung Bioepis en varios países europeos. El comunicado en el idioma original es la versión oficial y autori...
-
Riassunto: Samsung Bioepis avvia la commercializzazione di BYOOVIZ®, biosimilare di Lucentis (ranibizumab), in Europa
INCHEON, Corea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. oggi ha annunciato che l'azienda ha avviato la commercializzazione diretta di BYOOVIZ®, un biosimilare di Lucentis1 (ranibizumab), in Europa. Samsung Bioepis si è impegnata per garantire il trasferimento continuo dei diritti commerciali da Biogen all'originaria Samsung Bioepis, rendendo BYOOVIZ disponibile come marchio Samsung Bioepis in vari Paesi europei. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la...
-
Belkin发布全新屏幕保护产品系列并推出“日常磨损更换计划”,全面提升设备日常防护水平
拉斯维加斯--(BUSINESS WIRE)--(美国商业资讯)-- 作为一家深耕消费电子领域逾40年的领先品牌,Belkin今日宣布推出全新一代屏幕防护解决方案,并同步公布一项战略合作及全新的“日常磨损更换计划”,进一步彰显其持续守护设备安全、增强消费者使用信心的坚定承诺。此次发布包括七款全新屏幕保护产品、与ScreenSkinz达成的定制化合作,以及一项专为屏幕防护产品设计的更换保障计划,旨在为用户提供长期安心保障,确保其喜爱的设备始终安全无虞、保持最佳使用状态。 重磅登场:ScreenForce Titan系列——全屏防护的至臻之选 Titan SmartShield Titan SmartShield作为该系列的高端刚性屏幕保护产品,提供航天级抗冲击防护性能,强度最高可达传统玻璃的18倍*。产品采用9H表面硬度设计,并通过最高6.5英尺(约 2 米)跌落防护认证**,在实现卓越耐用性的同时,依然保持出色的显示清晰度。其先进的防反射涂层可在各种光照条件下呈现鲜明色彩与亮度表现;防尘粘合技术则可在安装过程中有效排除灰尘,确保贴合平整、观感无瑕。该产品在制造过程中最高使用60%再生材...